Arbutus Biopharma Corp (ABUS)
3.24 x 3 3.27 x 9
Post-market by (Cboe BZX)
3.23 -0.28 (-7.98%) 04/04/25 [NASDAQ]
3.24 x 3 3.27 x 9
Post-market 3.26 +0.03 (+0.93%) 19:51 ET
for Fri, Apr 4th, 2025
Try Excel 
Watch
-
Add or delete the symbol from one or more Watchlists.
-
Create New Watchlist
This name already in use.
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -69,920 | -72,849 | -69,456 | -76,247 | -63,745 |
| Depreciation Amortization | 1,380 | 1,404 | 1,427 | 1,753 | 1,978 |
| Accounts receivable | -633 | -424 | -453 | 413 | -108 |
| Other Working Capital | -2,829 | -18,233 | 29,243 | 925 | 431 |
| Other Operating Activity | 7,152 | 4,166 | 3,883 | 5,624 | 10,003 |
| Operating Cash Flow | $-64,850 | $-85,936 | $-35,356 | $-67,532 | $-51,441 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 164,639 | 132,270 | -74,430 | -11,869 | -12,180 |
| PPE Investments | -182 | -988 | -512 | -809 | -229 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -2,500 |
| Purchase Of Investment | -141,509 | -80,509 | N/A | N/A | N/A |
| Investing Cash Flow | $22,948 | $50,773 | $-74,942 | $-12,678 | $-14,909 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 51,996 | 30,647 | 31,814 | 137,236 | 86,746 |
| Financing Cash Flow | $51,996 | $30,647 | $31,814 | $137,236 | $86,746 |
| Exchange Rate Effect | -49 | 25 | -22 | 5 | 56 |
| Beginning Cash Position | 26,285 | 30,776 | 109,282 | 52,251 | 31,799 |
| End Cash Position | 36,330 | 26,285 | 30,776 | 109,282 | 52,251 |
| Net Cash Flow | $10,045 | $-4,491 | $-78,506 | $57,031 | $20,452 |
| Free Cash Flow | |||||
| Operating Cash Flow | -64,850 | -85,936 | -35,356 | -67,532 | -51,441 |
| Capital Expenditure | -182 | -1,008 | -512 | -809 | -229 |
| Free Cash Flow | -65,032 | -86,944 | -35,868 | -68,341 | -51,670 |